In a recent study posted to the bioRxiv* pre-print server, a team of researchers discussed the efficacy of ABP-310, a neutralizing antibody (nAb), against all tested severe acute respiratory syndrome ...
– ABP-450 doses of 150 units and 195 units showed treatment effect of 4.8 days and 5.0 days, respectively, in the mean change from baseline in monthly migraine days (MMD) at weeks 21-24 but did not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results